Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma

[Image: see text] Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer and is one of the most common forms of cancer worldwide. Aberrant signaling of the FGF19-FGFR4 pathway leads to HCC in mice and is hypothesized to be a driver in FGF19 amplified HCC in humans. Multiple s...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ACS Med Chem Lett
Auteurs principaux: Liu, Haibo, Niu, Deqiang, Tham Sjin, Robert Tjin, Dubrovskiy, Alex, Zhu, Zhendong, McDonald, Joseph J., Fahnoe, Kelly, Wang, Zhigang, Munson, Mark, Scholte, Andrew, Barrague, Matthieu, Fitzgerald, Maria, Liu, Jinyu, Kothe, Michael, Sun, Fangxian, Murtie, Joshua, Ge, Jie, Rocnik, Jennifer, Harvey, Darren, Ospina, Beatriz, Perron, Keli, Zheng, Gang, Shehu, Elvis, D’Agostino, Laura Akullian
Format: Artigo
Langue:Inglês
Publié: American Chemical Society 2020
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549259/
https://ncbi.nlm.nih.gov/pubmed/33062171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00601
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires